Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID) and methods of using them to treat a severe acute respiratory syndrome.

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID) and methods of using them to treat a severe acute respiratory syndrome.

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID); pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID); pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Compounds of formula (I), pharmaceutical compositions comprising compounds of the formula (I), and methods of treating an HIV infection comprising administering an effective amount of one or more compounds of formula (I), or a pharmaceutical composition comprising same.

Abstract: Bis-amide inhibitors of SARS-CoV-2 (COVID); pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

Abstract: Various embodiments of the present invention are directed to compounds of the formula (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof. The compounds disclosed herein are as inhibitors of HIV-1 protease and, as a result, are useful in the treatment of HIV infection.

Abstract: Disclosed is a method for acquiring information on exacerbation risk of COVID-19, comprising measuring IgM antibody against S antigen of SARS-CoV-2 contained in a specimen collected from a subject infected with SARS-CoV-2 or a subject suspected of suffering from COVID-19, wherein a value obtained by the measurement of IgM antibody serves as an index of exacerbation risk of COVID-19 of the subject.

Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Abstract: Described herein are compounds of the formulae (I), (Ia), (Ib), and (II) and pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods of making and using compounds of the formulae (I), (Ia), (Ib), and (II) to, among other things, treat HIV/AIDS.

Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 am defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Abstract: It is found that a nucleoside derivative represented by the following general formula (1) has an anti-viral activity and is less toxic to host cells. [in the formula, R1 represents a hydrogen or halogen atom, R2 represents a hydrogen or halogen atom, R3 represents a cyano group, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a halogen atom, or an azido group, R4 represents an amino group, a hydrogen atom, a halogen atom, or a hydroxy group, R5 represents a nitrogen atom or a methine group, R6 represents a hydrogen atom or a hydroxy group, and R7 represents a hydrogen atom or a hydroxy group].

Abstract: Described herein are compounds of the formulae (I), (Ia), (Ib), and (II) and pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods of making and using compounds of the formulae (I), (Ia), (Ib), and (II) to, among other things, treat HIV/AIDS.

Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.

Abstract: Various embodiments relate to a compound of the formula (I): wherein X, X1, R1—R4 and R7 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I), or a pharmaceutical compositions comprising compounds of the formula (I), to a patient in need thereof.

Abstract: It is found that a nucleoside derivative represented by the following general formula (1) has an anti-viral activity and is less toxic to host cells. [in the formula, R1 represents a hydrogen or halogen atom, R2 represents a hydrogen or halogen atom, R3 represents a cyano group, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, a halogen atom, or an azido group, R4 represents an amino group, a hydrogen atom, a halogen atom, or a hydroxy group, R5 represents a nitrogen atom or a methine group, R6 represents a hydrogen atom or a hydroxy group, and R7 represents a hydrogen atom or a hydroxy group.

Abstract: Various embodiments relate to a compound of the formula (I): wherein X, X1, R1-R4 and R7 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I), or a pharmaceutical compositions comprising compounds of the formula (I), to a patient in need thereof.